Table 2.
| a. Clinical characteristics of NOD2R CD patients. | |||||||
|---|---|---|---|---|---|---|---|
| Patient | NOD2 Genotype |
Age at Surgery (years) |
Disease Duration1 (years) |
Disease Behavior2 |
Sex | Race3 | Medication4 |
| 15* | R702W/WT | 37 | 10 | B2 | F | W | C,D |
| 196* | InsC/R702W | 24 | 7 | B3 | F | W | B |
| 235* | R702W/WT | 28 | 11 | B3 | M | W | B,D |
| 312* | InsC/InsC | 28 | 1 | B3 | F | W | B |
| 382 | InsC/G908R | 24 | 3 | B3 | M | W | A,B,C |
| 404 | R702W/WT | 24 | 0 | B3 | F | W | A,B,C,D |
| 442 | InsC/WT | 33 | 13 | B1 | M | W | C,D |
| b. Clinical characteristics of NOD2NR CD patients. | |||||||
|---|---|---|---|---|---|---|---|
| Patient | NOD2 Genotype |
Age at Surgery (years) |
Disease Duration1 (years) |
Disease Behavior2 |
Sex | Race3 | Medication4 |
| 16 | WT/WT | 40 | 4 | B2 | F | A | |
| 19* | WT/WT | 47 | 19 | B3 | M | W | B,C |
| 22* | WT/WT | 74 | 3 | B3 | M | W | A, D |
| 124* | WT/WT | 36 | 7 | B2 | M | W | A |
| 178 | WT/WT | 20 | 0 | B3 | F | W | B |
| 204 | WT/WT | 48 | 2 | B2 | M | B | A,C,D |
| 163 | WT/WT | 35 | 1 | B3 | F | B | A,C |
| 218 | WT/WT | 38 | 5 | B3 | M | W | B,C,D |
| 256* | WT/WT | 46 | 16 | B3 | M | W | A,D |
| 233 | WT/WT | 69 | 5 | B2 | F | W | A, C, D |
| 576 | WT/WT | 18 | 0 | B2 | M | W | B,C |
| C. Clinical characteristics of NOD2NR non-IBD control subjects. | |||||
|---|---|---|---|---|---|
| Sample | NOD2 Genotype |
Age at Surgery (years) |
Sex | Race1 | Diagnosis |
| N13* | WT/WT | 61 | M | W | Colonic inertia |
| N14 | WT/WT | 72 | M | W | Colon cancer |
| N15* | WT/WT | 71 | M | W | Colon cancer |
| N17* | WT/WT | 56 | F | W | Ileal nodule |
| N19 | WT/WT | 47 | F | W | Fistula, adenomatous polyp |
| N21 | WT/WT | 51 | M | B | Colonic inertia |
| N33* | WT/WT | 55 | F | W | Colonic inertia |
| N34* | WT/WT | 41 | F | W | Colonic inertia |
| N39 | WT/WT | 40 | F | W | Colonic inertia |
Disease duration is defined as Age at Surgery – Age of Diagnosis
Disease behavior at the time of surgery is defined using the Montreal Classification: B1 inflammatory (not stenosing or penetrating); B2, stenosing; B3, penetrating.
Race: W, white; B, black; A, asian.
Medication: A, 5-aminosalicylic acid; B, antibiotics (in addition to perioperative cefoxitin); C steroids; D immunomodulators (azathioprine, 6-mercaptopurine or methotrexate).
Samples selected for microarray analysis
Disease duration is defined as Age at Surgery – Age of Diagnosis
Disease behavior at the time of surgery is defined using the Montreal Classification: B1 inflammatory (not stenosing or penetrating); B2, stenosing; B3, penetrating.
Race: W, white; B, black; A, asian.
Medication: A, 5-aminosalicylic acid; B, antibiotics (in addition to perioperative cefoxitin); C steroids; D immunomodulators (azathioprine, 6-mercaptopurine or methotrexate).
Samples selected for microarray analysis
Race: W, white; B, black; A, asian.
Samples selected for microarray analysis